A shark VNAR-IL-15 fusion protein that suppresses TROP2+ tumor growth
- 30 January 2026
- journal article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 346, 150642
Abstract
No abstract availableKeywords
Funding Information
- Sanya Yazhou Bay Science and Technology City (SKJC-2022-01-002)
- Sanya Yazhou Bay Science and Technology City (SKJC-2024-03-001)
- Sanya Yazhou Bay Science and Technology City (DSTIC-CYCJ-2023012)
This publication has 62 references indexed in Scilit:
- A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapyActa Pharmaceutica Sinica B, 2024
- Targeting Trop-2 in cancer: Recent research progress and clinical applicationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronavirusesBiomedical Engineering Advances, 2022
- Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate AggregatesPharmaceutical Research, 2021
- Not so innocent: Impact of fluorophore chemistry on the in vivo properties of bioconjugatesCurrent Opinion in Chemical Biology, 2021
- Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cellsCancer Immunology, Immunotherapy, 2019
- Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse modelBiomedicine & Pharmacotherapy, 2019
- Immunocytokines for cancer treatment: past, present and futureCurrent Opinion in Immunology, 2016
- Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2Cancer Immunology, Immunotherapy, 1996
- Studies Evaluating the Antitumor Activity and Toxicity of Interleukin-15, a New T Cell Growth Factor: Comparison with Interleukin-2Cellular Immunology, 1995